Bicyclic BF3-Site Modulators for Resistant Androgen Receptor Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer and Kennedy's disease, such as Kennedy's disease, are inadequate due to the development of resistance to conventional anti-androgen drugs targeting the androgen receptor (AR) ligand-binding site, and there is a need for effective inhibitors of the novel Binding Function-3 (BF3) site on the AR to manage these conditions.
Innovation Solution
Development of bicyclic compounds that modulate androgen receptor (AR) activity by inhibiting the BF3 site, specifically targeting allosteric modifications to prevent AR interactions with co-activators, thereby reducing AR transcriptional activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-androgen drugs targeting the AR ligand-binding site are used, then initial therapeutic effect is achieved, but drug resistance develops over time
Solution Approach 1:
The patent extracts the inhibitory action from the conventional ligand-binding site target and relocates it to the BF3 site. By taking out the dependency on the ligand-binding site, the invention creates a new therapeutic pathway that bypasses the resistance mechanism developed against conventional drugs.
Solution Approach 2:
The BF3 site acts as an intermediary target between the drug and the final therapeutic effect. Instead of directly blocking the ligand-binding site, the compounds bind to BF3 and indirectly modulate AR activity, providing a new mechanism that overcomes resistance to direct ligand-binding site inhibitors.
2Adaptability or versatility
If new BF3 site-targeting compounds are developed, then potential to overcome drug resistance is achieved, but lack of clinical data exists
Solution Approach 1:
The patent performs preliminary validation of the BF3 site as a drug target by demonstrating that bicyclic compounds can bind to and modulate AR activity through this site. This preliminary action establishes the proof-of-concept and creates a foundation for future clinical development, reducing the information gap about BF3 site targeting.
3Productivity
If AR transcriptional activity is strongly inhibited, then cancer cell growth is suppressed, but potential side effects on normal androgen-dependent tissues increase
Solution Approach 1:
The patent applies local quality by targeting a specific functional site (BF3) rather than globally blocking all AR activity. The BF3 site is involved in transcriptional activation but is distinct from the ligand-binding site, allowing for selective modulation of AR functions. This localized targeting approach may preserve essential androgen-dependent functions in normal tissues while suppressing cancer cell growth.
Data Source
AI summary
Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease and for the treatment of cancer.